

Dicot Pharma announces last day of trading in BTU and first day of trading in warrants of series TO 7

Uppsala, Sweden, June 24, 2026. Dicot Pharma AB's rights issue of units, for which the subscription period ended on June 4, 2026 (the "Rights Issue"), has now been registered with the Swedish Companies Registration Office and paid subscribed units ("BTU") will be replaced by shares and warrants of series TO 7. The last day of trading in BTU on Nasdaq First North Growth Market is June 25, 2026, and the first day of trading in warrants of series TO 7 is July 1, 2026.

The last day of trading in BTU is June 25, 2026 and the conversion date for BTU is June 29, 2026. The new shares and warrants are expected to be credited to each shareholder's VP account/custody account on or around July 1, 2026. The first day of trading in warrants of series TO 7 is July 1, 2026 and the last day of trading is May 20, 2027.

For further information, please contact:

Elin Trampe, CEO

Phone: +46 72 502 10 10

E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 16,750 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.